Clinical trials: Disease Transmission, Infectious
HPV Infection
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the…
- Trial name
- NCT04965350
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HIV-1, HIV Infections
A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
This three stage study will evaluate the safety and tolerability of MRKAd5 HIV-1 Gag Vaccine. In Stage I subjects will be randomized to receive the vaccine at 1x10^9 viral particles/dose (vp/d) or placebo.
- Trial name
- NCT00849732
- Testing
- V520, Comparator: V520 (1x10^9 vp/d), Comparator: V520 (1x10^10 vp/d)
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1
A Study of CL-197 Capsules in Healthy Participants
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of CL-197 capsules in health conditions.
- Trial name
- NCT05944848
- Testing
- 1 mg CL-197 capsules
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Infection, Human Immunodeficiency Virus I, HIV Infection
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in…
- Trial name
- NCT00046176
- Testing
- abacavir/lamivudine, abacavir, lamivudine
- Where
- 56 sites in United States, Costa Rica and 2 more
- Volunteers
- 240 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus, HIV
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of an islatravir (ISL)-eluting implant.
- Trial name
- NCT05115838
- Testing
- Islatravir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.
- Trial name
- NCT00140725
- Testing
- Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Sexually Transmitted Diseases
Effects of LiveSpo X-secret in Supporting Treatment of Sexually Transmitted Diseases
Sexually Transmitted Infections (STIs) are common gynecological infections worldwide, especially in tropical and underdeveloped countries, primarily affecting the reproductive age group.
- Trial name
- NCT05783856
- Testing
- LiveSpo X-secret, 0.9% NaCl physiological saline
- Where
- Vietnam
- Volunteers
- 100 people
- Sponsor
- Anabio R&D
Healthy
Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
The primary purpose of this study is to assess safety, tolerability of the different vaccine schedules (different regimen durations and different number of dose administrations) with Ad26.Mos.HIV and Clade C Glycoprotein (gp) 140…
- Trial name
- NCT02685020
- Testing
- Ad26.Mos.HIV, Clade C gp140
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hepatitis B
Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule
Hepatitis B virus (HBV) infection is an important global health problem, and the WHO adopted a strategy to eliminate HBV infection as a public health threat by the year 2030.
- Trial name
- NEOVAC2BK (NCT04029454)
- Testing
- birth dose vaccination against hepatitis B strategy
- Where
- 2 sites in Burkina Faso
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
HIV Infections
A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method
The proposed study is a multi-centre, open-label crossover study to assess the safety and acceptability of a silicone elastomer vaginal ring (containing no drug) when inserted for a 12 week period in 200 healthy, sexually active…
- Trial name
- NCT00469170
- Testing
- intravaginal ring
- Where
- 4 sites in South Africa, Tanzania
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Congenital Cytomegalovirus Infection
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
A phase 3, open-label, single-arm, prospective, multi-center trial of Cytotect CP Biotest (BT097) for prevention of maternal-fetal CMV transmission after primary maternal CMV infection.
- Trial name
- PreCyssion (NCT05170269)
- Testing
- BT097
- Where
- 5 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Biotest
Genital Warts
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00735462
- Testing
- 2.5% imiquimod cream, 3.75% imiquimod cream
- Where
- 43 sites in United States
- Volunteers
- 511 people
- Sponsor
- Graceway Pharmaceuticals, LLC
HIV Infections
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children ≥3 months to <6 years of age.
- Trial name
- PRINCE1 (NCT01099579)
- Testing
- Atazanavir powder, Ritonavir oral solution, Atazanavir capsules
- Where
- 18 sites in Brazil, Chile and 4 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
- Trial name
- NCT00002170
- Testing
- Nelfinavir mesylate
- Where
- 5 sites in United States
- Sponsor
- Agouron Pharmaceuticals
HIV, HIV Infection
Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
This research study is being carried out to study a new way to possibly treat human immunodeficiency virus (HIV). The agent is called SB-728-T which are CD4+ T-cells obtained from an individual that are genetically modified at…
- Trial name
- NCT01252641
- Testing
- SB-728-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sangamo Therapeutics
Hepatitis B, Chronic, Pregnancy Related
Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B
Immunoprophylaxis failure of hepatitis B (HBV) remains a concern and has been reported in approximately 10-30% of infants born to highly viremic mothers with HBeAg-positive.
- Trial name
- NCT04211805
- Testing
- Tenofovir Alafenamide 25 MG for arm (A), Tenofovir Disoproxil Fumarate 300mg for arm (B)
- Where
- 11 sites in China
- Volunteers
- 450 people
- Sponsor
- New Discovery LLC
Human Immunodeficiency Virus (HIV)
Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV infection is considered to be a chronic disease requiring lifelong therapy.
- Trial name
- NCT04554966
- Testing
- ABBV-382
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 54 people
- Sponsor
- AbbVie
HIV Infections
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV…
- Trial name
- NCT00025727
- Testing
- Lopinavir/Ritonavir, Ritonavir, GW433908
- Where
- 32 sites in United States
- Volunteers
- 330 people
- Sponsor
- GlaxoSmithKline
Bites Monkey
Virus Transmission to People Recently Bitten or With a History of Monkey Bites "SIMVIR
Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens.
- Trial name
- SIMVIR (NCT07097480)
- Testing
- Blood samples collection, Saliva samples collection
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Pasteur
HIV-infection/AIDS
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.
- Trial name
- NCT01827540
- Testing
- Cenicriviroc, Dolutegravir, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tobira Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.